GET DAILY SIGNALSJohnson & Johnson (JNJ): +5% Recovery as Pharma Strength Offsets One-Time Charges and MedTech Softness
Key Takeaways
- Johnson & Johnson shares traded near $272 in early November, up roughly 5% over the trailing 30 days after a sharp post-earnings dip and subsequent recovery.
- Third-quarter 2026 revenue of $25.4 billion and adjusted EPS of $2.59 topped consensus, while reported EPS fell to $0.09 on roughly $7 billion in talc- and deal-related charges.
- Innovative Medicine delivered about 7.9% operational growth, led by oncology, while the MedTech segment lagged with 2.5% growth amid international headwinds.
- Management raised full-year 2026 sales and adjusted earnings guidance and reiterated a path toward exceeding $100 billion in annual revenue for the first time in the company's history.
- The proposed talc litigation resolution and the planned DePuy Synthes separation remain key structural factors for investors to monitor.
- For deeper valuation and results detail, explore Johnson & Johnson's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see top-performing automated trading strategies across thousands of tickers.
Recent Price Action and Market Position
Johnson & Johnson (JNJ) has traded in a volatile but ultimately constructive range over the trailing month. After reaching the low $250s in early October, shares slipped further following the October 13 third-quarter earnings release before recovering toward the $272 area by early November. The stock's roughly 5% gain over the past 30 days reflects a market that weighed one-time charges and MedTech softness against stronger-than-expected pharmaceutical results and an upwardly revised outlook.
With a market capitalization near $650 billion and a dividend yield around 2%, JNJ retains its profile as a large-cap, defensive healthcare holding. Sentiment remains broadly positive, with sell-side consensus at Strong Buy and an average price target near $289, though near-term trading has been shaped by litigation headlines and segment-level divergence rather than a single macro catalyst. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Understanding JNJ's Core Operations
Johnson & Johnson is a diversified healthcare company operating across two primary segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The pharmaceutical portfolio spans oncology, immunology, neuroscience, cardiovascular, and infectious disease, anchored by blockbusters such as Darzalex, Tremfya, Carvykti, and Rybrevant. The MedTech business covers cardiovascular devices, surgery, orthopaedics, and vision, including products like the OTTAVA robotic surgical system and Abiomed's Impella heart pumps.
Investors follow JNJ for its scale, product breadth, and consistent free-cash-flow generation, which supports a long-running dividend and steady research investment. The company's oncology franchise has become its primary growth engine, while newer immunology products such as Tremfya are helping offset declining sales of Stelara, which now faces biosimilar competition. This diversification positions JNJ as a bellwether for both the pharmaceutical and medical-device industries. From what I see, the balance across these areas provides a solid foundation even when one segment faces temporary pressure.
Q3 2026 Results and Key Events
The dominant event of the trailing month was JNJ's third-quarter 2026 report. Worldwide sales rose 5.9% to $25.4 billion, and adjusted earnings of $2.59 per share beat consensus of roughly $2.52 to $2.53. However, reported net earnings collapsed to $210 million, or $0.09 per share, reflecting approximately $7 billion in charges tied to the proposed talc litigation resolution, the $1 billion acquisition of Firefly Bio, and a collaboration with Cell BioMedicines (Sail Biomedicines) to advance in vivo CAR T therapies.
Innovative Medicine sales grew about 7.9% operationally to $16.8 billion, with oncology up roughly 17%. Tremfya surged 68%, while Darzalex, Carvykti, Tecvayli, and Rybrevant all posted double-digit growth. In contrast, MedTech grew only 2.5% to $8.64 billion, pressured by China procurement policies, Middle East disruptions, and European budget constraints; Abiomed sales declined 1.5%.
On the regulatory front, the company received FDA authorization for its OTTAVA robotic surgical system and approval of IMAAVY for warm autoimmune hemolytic anemia. JNJ also declared a fourth-quarter dividend of $1.34 per share and raised its full-year guidance to reported sales of roughly $101.2 billion and adjusted EPS of $11.10 at the midpoint. One thing that stands out is how the pharma momentum helped offset the headline noise from the charges.
2026 Outlook and What Investors Should Watch
Looking ahead, several factors will shape JNJ's trajectory through 2026 and into 2027. Management has reiterated confidence in achieving double-digit growth by the end of the decade, and a December 8 enterprise business review is expected to provide additional detail on the 2027 outlook and earlier-stage pipeline. Investors will also watch the ramp of OTTAVA in the robotic surgery market and whether MedTech can stabilize internationally after recent weakness in cardiovascular and surgery outside the U.S.
The planned separation of the DePuy Synthes orthopaedics business, targeted for mid-2027, remains a key structural catalyst, while the proposed $5.5 billion ovarian talc resolution—conditional on meeting a 95% claimant participation threshold—carries both litigation and execution risk. The Firefly Bio and Cell BioMedicines transactions are expected to dilute full-year 2027 adjusted earnings by a combined $1.36 per share. Currency movements and U.S. drug-pricing reform add further variables, with the next earnings report estimated for late January 2027. I’m watching this closely as the structural moves unfold.
Exploring AI-Assisted Trading Tools
In my own analysis, I frequently review Tickeron’s Trending AI Robots page to compare automated strategies across a wide range of tickers. It highlights top-performing bots with different risk levels and timeframes, which helps me evaluate systematic approaches that align with longer-term holdings like JNJ. The data-driven view offers a practical way to cross-check ideas without replacing fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
JNJ in upward trend: 10-day moving average broke above 50-day moving average on October 30, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Oscillator exited the oversold zone, 17 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 38 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 19 of 47 cases over the following month. The odds of a continued upward trend are 40%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.360). P/E Ratio (31.640) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement